Pradaxa (Dabigatran Etexilate Mesylate) Patent Expiration, LOE Window & CMS Spending

Pradaxa (Dabigatran Etexilate Mesylate) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2026-03-07 (last listed 2031-07-20), 8 AB generics, $131.9M 2024 CMS Part D & Medicaid spend, and $4,717 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN022512 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2026-03-07
Last Listed Patent or Exclusivity Date2031-07-20
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$131.9M
2024 Medicare Part D Spend$123.2M
2024 Medicaid Spend$8.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,717 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.